People
EnteroBiotix Granted MHRA License, Names CEO
10 September 2018 - - UK-based clinical stage microbiome therapeutics company EnteroBiotix has been granted a manufacturers 'specials' license from the Medicines and Healthcare Products Regulatory Agency to further its therapeutic and product pipeline, the company said.

EnteroBiotix has also appointed senior biotechnology executive Dr James Clark PhD as CEO, with founder Dr James McIIroy moving to the role of chief business officer in order to support the new CEO and accommodate NHS hospital requirements to complete his medical training as a clinician.

James Clark brings over 20 years of biotechnology and biopharmaceutical drug discovery, development and commercialisation experience to EnteroBiotix.

Previous roles have included chief technical officer at Enterome, one of Europe's leading microbiome companies, and most recently vice-president of clinical laboratory operations at Inivata, the global clinical cancer genomics group.

EnteroBiotix is developing novel medicinal products targeting the gut microbiome to serve patients with serious unmet clinical needs.

The company has established fully integrated ISO-accredited microbial collection and GMP-compliant processing capabilities under a 'specials' license from the MHRA.

Headquartered in Aberdeen, EnteroBiotix has to date raised over GBP 2m in equity investment and non-dilutive funding with a dedicated core team supported by an independent Scientific and Medical advisory board.
Login
Username:

Password: